米国の全身麻酔薬の市場規模、シェア、動向分析レポート：医薬品別、投与経路別、最終用途別、用途別、国別、セグメント予測、2025年～2030年

米国の全身麻酔薬市場の成長と動向：

Grand View Research, Inc.によると、米国の全身麻酔薬市場規模は2030年までに20億3,000万米ドルに達すると予測され、2025年から2030年にかけてCAGR 2.82％で成長すると予測されています。

この成長を牽引しているのは、主に手術件数の増加です。米国麻酔科学会（ASA）は、人口の高齢化、慢性疾患の有病率の増加、手術技術の進歩に起因する手術の一貫した増加を強調しています。CDCは2024年2月に、約1億2,900万人のアメリカ人が、がん、心臓病、糖尿病、高血圧などの主要な慢性疾患を少なくとも1つ持っていると報告しました。このように慢性疾患の有病率が高いため、心臓血管やその他の手術が数多く必要となり、その結果、効果的な全身麻酔薬の需要が高まっています。

麻酔技術の進歩も重要な促進要因です。レミフェンタニルのような超短時間作用型麻酔薬などの技術革新は、麻酔深度のコントロールの向上と回復時間の短縮をもたらし、患者の転帰を向上させ、市場の成長を促進します。さらに、自動麻酔デリバリー・システムを含む高度なデリバリー・システムとモニタリング技術の開発は、精度と安全性を向上させることで麻酔診療に革命をもたらしています。

規制の開発も重要な役割を果たしています。FDAの画期的治療薬に対する迅速承認パスウェイは、新しく効果的な麻酔薬への迅速なアクセスを促進しています。例えば、新規の徐放性麻酔薬であるZYNRELEFTMの最近の承認は、規制の進歩がいかに革新的な製品の導入を支えているかを示しています。

米国全身麻酔薬市場レポート・ハイライト

• 医薬品別では、プロポフォール部門が2024年に25.52%の大幅な収益シェアで市場を席巻し、予測期間中に最も速いCAGRで成長する見込みです。
• 投与経路別では、静脈内投与が2024年に最大の収益シェアを占め、予測期間中も3.03％のCAGRで急成長が見込まれています。
• 用途別では、人工膝関節置換術と人工股関節置換術が市場を席巻し、大きな収益シェアを獲得しています。
• 最終用途別では、病院分野が市場を独占し、2024年には67.05％の大幅な収益シェアを獲得しました。病院は、全身麻酔を必要とする大手術や複雑な医療処置の主な舞台です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の全身麻酔薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連 / 付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の全身麻酔薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の全身麻cc酔薬市場：医薬品推定・動向分析

• 医薬品ダッシュボード
• 医薬品の変動分析
• 医薬品別、収益別
• セボフルラン
• プロポフォール
• デクスメデトミジン
• レミフェンタニル
• デスフルラン
• ミダゾラム
• その他

第5章 米国の全身麻酔薬市場：投与経路の推定・動向分析

• 投与経路ダッシュボード
• 投与経路の変動分析
• 投与経路別、収益
• 静脈内
• 吸入

第6章 米国の全身麻酔薬市場：最終用途の推定・動向分析

• 最終用途ダッシュボード
• 最終用途変動分析
• 最終用途別、収益
• 病院
• 外来手術センター
• その他

第7章 米国の全身麻酔薬市場：用途推定・動向分析

• 用途ダッシュボード
• 用途変動分析
• 用途別、収益
• 心臓手術
• がん
• 一般外科
• 膝関節および股関節の置換
• その他

第8章 米国の全身麻酔薬市場：医薬品、投与経路、最終用途および用途別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
  • 米国

第9章 競合情勢

• 企業 / 競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key company market share analysis, 2024
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE &Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories

List of Tables

• Table 1 List Of Abbreviation
• Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
• Fig. 10 Colorectal Surgery Competitive Insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
• Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
• Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
• Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
• Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
• Fig. 19 Propofol market estimates and forecast, 2018 - 2030
• Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
• Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
• Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
• Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
• Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
• Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
• Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
• Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
• Fig. 33 Others market estimates and forecast, 2018 - 2030
• Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
• Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
• Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
• Fig. 37 Cancer market estimates and forecast, 2018 - 2030
• Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
• Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
• Fig. 40 Other market estimates and forecast, 2018 - 2030
• Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market

U.S. General Anesthesia Drugs Market Growth & Trends:

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.82% from 2025 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights:

• Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.52% in 2024 and is also expected to grow at the fastest CAGR during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
• Based on route of administration, the intravenous segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.03% during the forecast period
• Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
• Based on end-use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05% in 2024. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Application
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Volume Of Surgical Procedures
    • 3.2.1.2. Advancements In Anesthesia Technology
    • 3.2.1.3. Regulatory Developments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory and Compliance Challenges
    • 3.2.2.2. Adverse Effects and Safety Concerns
• 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

• 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
• 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
• 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
• 4.4. Sevoflurane
  • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Propofol
  • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Dexmedetomidine
  • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Remifentanil
  • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Desflurane
  • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Midazolam
  • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
• 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
• 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Intravenous
  • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

• 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
• 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
• 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

• 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
• 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
• 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 7.4. Heart Surgeries
  • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. General Surgery
  • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Knee and hip replacements
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other
  • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.2.1. U.S.
    • 8.2.1.1. Key country dynamics
    • 8.2.1.2. Regulatory framework/ reimbursement structure
    • 8.2.1.3. Competitive scenario
    • 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2024
  • 9.2.3. Baxter International Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Drug benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. AstraZeneca
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Drug benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. AbbVie Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Drug benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. B. Braun Melsungen AG
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Drug benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Fresenius SE & Co. KgaA
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Drug benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Pfizer
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Drug benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Hospira Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Drug benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Aspen Pharmacare Holdings Limited
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Drug benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Hikama Pharmaceuticals plc
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Drug benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Abbott Laboratories
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Drug benchmarking
    • 9.2.12.4. Strategic initiatives